Global Women’s Health Market Report Segmented by Product Type (ACTONEL, FORTEO, Mirena, NuvaRing, Premarin), Application (Female Infertility, Menopause, Endometriosis), Age Group (Adolescents, Adult Women, Elderly Women), End-user & Forecast to 2030

One-half of the world’s population is women, and they account for ~80% of consumer purchasing decisions in the healthcare industry. Women’s health refers to the branch of medicine that focuses on the biological, psychological, and social factors affecting the health and well-being of women throughout their lives. The central focus is on reproductive care, which includes menstruation, contraception, pregnancy, childbirth, and menopause. Additionally, it also addresses the management of other reproductive system disorders such as polycystic ovary syndrome (PCOS), endometriosis, and gynecological cancers like cervical and ovarian cancer.

Beyond reproductive health, women are also at higher risk for several non-reproductive conditions, such as osteoporosis, which is more prevalent in women due to hormonal changes that affect bone density, especially after menopause. Breast cancer remains one of the most prevalent and serious threats to women's health globally. Understanding these unique women’s health concerns is vital to improve early diagnosis, access to treatment or care, and health outcomes for women at every life stage.

To learn more about this report, download the PDF brochure

Growing Burden of Chronic Illness in Women

The increasing incidence of chronic conditions among women, such as cancer and osteoporosis, is the major growth driver of the market. These conditions often require gender-specific measures for prevention, diagnosis, and treatment. The risk factors associated with the occurrence of such diseases are family history, increasing age, early onset of periods or menopause and obesity, among others. For example, in March 2021, the World Health Organization (WHO) initiated the Global Breast Cancer Initiative (GBCI) intending to decrease breast cancer mortality rates by 2.5% annually until 2040, thereby potentially saving 2.5 million lives. With the growing focus on prevention and awareness programs, more women are being diagnosed with critical health conditions, driving the demand for products and services designed for women’s health care. For instance,

• In February 2024, Hologic, Inc. launched the first digital cytology system using advanced volumetric imaging for the detection of precancerous and cervical cancer cells in the US

Rising Demand for Contraceptives to Drive the Women’s Health Market

The growing demand for contraceptives is a significant driver for the women's health market. As awareness about family planning and reproductive health increases, more women are opting for various contraceptive methods to control their fertility and prevent unintended pregnancies. This demand is fueled by educational initiatives, improved access to healthcare services, and a shift towards proactive health management. Contraceptives, including oral pills, intrauterine devices (IUDs), implants, and injectables, offer women the ability to plan their families and careers, contributing to better overall health and economic stability. Additionally, the rise of new and improved contraceptive technologies, such as long-acting reversible contraceptives (LARCs), provides more options that cater to different preferences and needs. Government and non-governmental organizations' efforts to promote contraceptive use and improve accessibility, particularly in developing regions, further bolster this market

To learn more about this report, download the PDF brochure

Technological innovations in women’s healthcare

Advancements in diagnostic technologies have enabled early and precise detection of diseases such as breast cancer, osteoporosis, and reproductive disorders. Digital health tools such as telehealth platforms, mobile apps and wearable devices are now assisting women to take care of their health in a more personalized way. These tools enable continuous health tracking, symptom monitoring, medication reminders, and virtual consultations, increasing accessibility to care, especially in remote and underserved areas. Further, the integration of AI & M/L in the diagnosis and treatment of various diseases has created new opportunities and demands in the market.

• In January 2025, GE HealthCare introduced its enhanced Voluson Expert Series (models 22, 20, 18), which received FDA‑clearance, featuring AI-powered imaging, advanced automation (like SonoLyst and Graphicflow), and ergonomic design to boost early detection and exam efficiency in women’s health ultrasound
• In March 2024, Sirio Pharma unveiled a personalized 25‑formulation women’s health platform at Vitafoods Europe, featuring gummies and softgels tailored to life stages from puberty through menopause, addressing PMS, fertility, prenatal/postnatal care, UTI protection, gut health, weight management, sleep, and menopausal wellbeing
• In February 2023, Samsung HERA W10 Elite ultrasound system was launched, which was designed for Obstetrics and Gynecology, offering advanced imaging capabilities and AI-powered tools

Emerging Opportunities in Women’s Health Market

A new era of innovation is unfolding in women’s health, which is driven by groundbreaking scientific and technological advancements, thereby offering transformative opportunities to address long-standing gaps in diagnosis, treatment, and care. Conditions such as preeclampsia, endometriosis, and hormone-related disorders—are now being explored with greater precision and purpose. Emerging fields like genomics, tissue engineering, artificial intelligence, and cell and gene therapy are unlocking novel ways to develop targeted solutions for female-specific health challenges. For example, researchers are studying transcriptomics (the study of RNA molecules in a cell) for treating elusive conditions such as preeclampsia or preterm birth. On the other hand, tissue engineering is being used to create uterine organoids to push the knowledge frontier on endometriosis. Genomics is another research area that can help researchers in realizing the potential of personalized medicine. There has been extraordinary growth in terms of technology from predictive AI solutions to modelling unique DNA profiles, which uses machine learning algorithms to analyse user data to provide unique, actionable insights and treatment plans related to symptom progression. A favourable environment for research activities is expected to further drive growth opportunities in this market.

“Women’s health is not a niche market; it includes much more than just maternal or reproductive care. Indeed, women’s healthcare presents enormous opportunities for value creation and for improving the lives and livelihoods of women, with positive effects that redound across society"

- Executive Vice President, Global Operations and Supply Chain, Women’s Health Company, United States

Product Type Segment Analysis

The women’s health market comprises two products like: ACTONEL, YAZ (Yasmin, Yasminelle), FORTEO, Mirena, NuvaRing, ORTHO TRI-CY LO, Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa, Others. The Prolia segment is likely to lead the market and is projected to grow at the fastest rate over the forecast period. Prolia, whose generic name is denosumab, is a medication used in women's health for treating and preventing osteoporosis in postmenopausal women. It is widely used for the treatment of osteoporosis in postmenopausal women at high risk of fractures. Prolia has established a significant market presence due to its effectiveness in reducing the incidence of fractures and its biannual dosing regimen, which improves patient compliance compared to other osteoporosis treatments.

The Minastrin 24 Fe segment is expected to grow at a lucrative CAGR over the forecast period due to its user-friendly dosing schedule and minimal side effects. It combines low-dose estrogen with progestin and iron, which helps manage both birth control and iron deficiency, appealing to women seeking dual benefits. The 24-day active pill regimen, with fewer placebo days, is preferred for its convenience and reduced occurrence of withdrawal bleeding. Additionally, increasing awareness of hormonal contraception's benefits and growing demand for effective, well-tolerated contraceptive options contribute to Minastrin 24 Fe's expanding market presence.

Application Type Segment Analysis

The women’s health market can be analyzed based on application types, such as Female Infertility, Contraceptives, Postmenopausal osteoporosis, Endometriosis, Menopause, and Others. The contraceptives represent the largest segment. The widespread use of contraceptives for both pregnancy prevention and management of menstrual-related issues drives this large market segment. Contraceptives benefit from extensive awareness, strong demand, and ongoing innovation, which maintains their dominant position. The fastest-growing segment is postmenopausal osteoporosis. The incidence of osteoporosis among postmenopausal women is increasing continuously. This growth is driven by an aging demographic, rising awareness of bone health, and advancements in treatment options. Additionally, increased focus on preventive care and proactive management of bone density is accelerating growth in this area. The combination of a growing patient population and a heightened emphasis on osteoporosis prevention and treatment supports its position as the fastest-growing segment in the women’s health market.

Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting different growth strategies such as new product launches and approvals to garner market share. For instance,

• In May 2024, The FDA approved Sandoz’s Jubbonti and Wyost as interchangeable biosimilars to Prolia and Xgeva, respectively, for treating certain types of osteoporosis and preventing bone events in cancer. These approvals enhance treatment accessibility and demonstrate the biosimilars' similar safety and efficacy to their reference products
• In January 2024, Bayer Healthcare’s Mirena, a 52mg Levonorgestrel IUD, received FDA approval for contraceptive to extend of this device, for contraception only, to eight years. The approval is particularly beneficial for younger perimenopausal women needing contraception, while the license for treating heavy menstrual bleeding and endometrial protection remains unchanged
• In November 2023, Teva Pharmaceuticals received USFDA of a generic version of Forteo (teriparatide injection) for osteoporosis treatment. This approval enhances patient access to osteoporosis treatment and supports Teva’s goal of maintaining its position as a leading generic pharmaceutical company

The women’s health market is expected to gain further momentum in the coming years due to impending patent cliff, rising R&D investments, new product launches, and aggressive organic and inorganic growth strategies followed by the players.

Competitive Landscape Analysis

The global women’s health market is marked by the presence of established and emerging market players such as Bayer AG, Amgen, AbbVie, Pfizer, Ferring Pharmaceutical, Novartis, Organon & Co., Apothecus Pharmaceutical Corp, Theramex, and Blairex Laboratories. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Global Women’s Health Market Segmentation

This report by Medi-Tech Insights provides the size of the global women’s health market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product type, application, age group and end-user.

Market Size & Forecast (2023-2030), By Product Type, USD Million

• ACTONEL
• YAZ, Yasmin, Yasminelle
• FORTEO
• Mirena
• NuvaRing
• ORTHO TRI-CY LO
• Premarin
• Prolia
• Reclast/Aclasta
• XGEVA
• Zometa
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Female Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Menopause
• Endometriosis
• Others

Market Size & Forecast (2023-2030), By Age Group, USD Million

• Adolescents
• Adult Women
• Elderly Women

Market Size & Forecast (2023-2030), By End-user, USD Million

• Hospitals
• Clinics
• Homecare settings
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Key Strategic Questions Addressed

• What is the market size & forecast of the women’s health market?
• What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the women’s health market?
• What are the key trends defining the market?
• What are the major factors impacting the market?
• What are the opportunities prevailing in the market?
• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
• Who are the major players operating in the market?
• What are the key strategies adopted by players?